Mystic Ventures is an early-stage biotechnology venture fund that invests in companies focused on psychedelic medicine and consciousness expansion, aiming to address mental health crises through innovative solutions.
Key people at Mystic Ventures.
Key people at Mystic Ventures.
# Mystic Ventures: Pioneering Psychedelic Medicine Investment
Mystic Ventures is a venture capital firm dedicated to advancing the psychedelic medicine and mental health sector through strategic early-stage investments[1]. Founded in 2021 and based in Los Angeles, the firm operates with a clear mission: to democratize access to psychedelic-based treatments for conditions including depression, anxiety, PTSD, and other mental health disorders[1]. The fund's investment philosophy centers on backing pre-seed and seed-stage startups that are developing innovative, cost-effective psychedelic therapies, positioning itself at the intersection of biotech innovation and mental health transformation[1][2].
Mystic Ventures takes a biotech-oriented approach, leveraging partnerships with scientific research teams and pharmaceutical experts to validate startup theses and accelerate the commercialization of breakthrough treatments[2]. By operating through a rolling fund structure on AngelList, the firm offers flexible capital deployment—deploying close to $1 million per quarter as of mid-2023, with ambitions to double or triple that capacity[2]. The fund has already backed notable companies like Psylo and Heading Health, demonstrating early traction in identifying promising ventures within this emerging therapeutic space[1].
Mystic Ventures was established in 2021 by Jeremy Gardner and Brock Pierce, both seasoned entrepreneurs and investors with extensive track records in emerging technology sectors[1]. Brock Pierce brings particular credibility to the venture, having held leadership roles across blockchain and fintech companies including Block.one, Tether, BitGo, and Blockchain Capital[3]. This founding team's background in identifying and scaling transformative technologies positioned them uniquely to recognize the inflection point in psychedelic medicine research and commercialization.
The firm's emergence reflects a broader inflection point in psychedelic therapeutics. As regulatory frameworks began shifting—particularly with FDA breakthrough therapy designations for psilocybin and MDMA-assisted treatments—Gardner and Pierce recognized an opportunity to build institutional capital around this nascent sector. Rather than waiting for the space to mature, they chose to enter early, backing founders who were pioneering high-quality psychedelic experiences and clinical applications[2].
Unlike traditional venture funds with fixed closing dates and capital calls, Mystic Ventures employs a rolling fund model that reduces liquidity requirements for limited partners[2]. This structure allows the firm to deploy capital more dynamically, with quarterly subscription minimums of $25,000 and an 8-quarter minimum commitment period[2]. The approach enables faster decision-making on high-conviction bets and allows the fund to scale capital deployment as opportunities emerge.
The fund explicitly leverages an expansive network of pedigreed physicians, researchers, founders, and entrepreneurs to validate startup theses and conduct rigorous due diligence[2]. This network advantage is particularly valuable in psychedelic medicine, where scientific credibility and regulatory expertise are critical to success. The firm's reach throughout the broader investing world and growing connections within the psychedelic community provide deal flow advantages that newer entrants cannot easily replicate.
Rather than treating psychedelic companies as lifestyle or wellness plays, Mystic Ventures positions itself as a biotech investor[1]. This orientation means the fund prioritizes scientific rigor, clinical validation, and pharmaceutical-grade development processes—differentiating it from purely consumer-focused psychedelic platforms and positioning portfolio companies for institutional credibility and regulatory approval.
The fund's stated focus on "world-class, dynamic founders" reflects a conviction that the psychedelic medicine space will be won by exceptional teams, not just novel molecules[2]. This founder-first approach aligns capital with the individuals most likely to navigate the complex regulatory, scientific, and commercial challenges ahead.
Mystic Ventures operates at the convergence of three powerful trends: the mental health crisis, regulatory reform, and venture capital's increasing appetite for alternative therapeutics. The global mental health burden—with depression and anxiety affecting hundreds of millions—has created urgent demand for novel treatments beyond traditional SSRIs and talk therapy[1]. Simultaneously, regulatory bodies including the FDA have begun recognizing psilocybin and MDMA-assisted therapy as breakthrough treatments, creating a pathway to commercialization that didn't exist five years prior.
The firm's emergence also reflects a maturation of venture capital's risk appetite. Early psychedelic companies faced significant stigma and regulatory uncertainty, making them unattractive to traditional institutional investors. By establishing a dedicated fund with experienced leadership, Mystic Ventures has helped legitimize psychedelic medicine as an investable category, signaling to other VCs and institutional LPs that the space warrants serious capital allocation. This legitimization effect extends beyond the fund itself—it validates the entire ecosystem of founders, researchers, and service providers working in psychedelic therapeutics.
Within the startup ecosystem, Mystic Ventures plays a crucial role as a patient capital provider willing to back companies through extended clinical development cycles and regulatory processes. Unlike consumer-focused venture funds that expect rapid user growth and revenue scaling, Mystic Ventures understands that psychedelic medicine companies may require 5-10 years to achieve clinical validation and regulatory approval. This patient capital is essential for the sector's development.
Mystic Ventures is positioned to become a defining investor in psychedelic medicine's institutional phase. As the sector transitions from fringe research to mainstream clinical practice, the fund's combination of early-stage capital, scientific credibility, and founder support will likely prove increasingly valuable. The firm's track record of 28 investments with a historical average check size of $356,000 and maximum checks reaching $8 million demonstrates both breadth of deal flow and willingness to scale capital into conviction bets[1].
Looking ahead, several dynamics will shape Mystic Ventures' trajectory. First, regulatory approvals for psilocybin and MDMA therapies will likely accelerate over the next 2-3 years, creating exit opportunities for early investors and validating the fund's thesis. Second, as psychedelic medicine becomes mainstream, competition for deal flow will intensify—requiring Mystic Ventures to deepen its network advantages and operational support capabilities. Third, the fund's ability to deploy capital at scale (potentially doubling or tripling quarterly deployment rates) will determine whether it captures the most promising founders or loses them to larger, better-capitalized competitors[2].
The broader implication is that Mystic Ventures represents a new model for venture capital: specialized, thesis-driven funds that enter emerging categories early, build deep networks, and provide patient capital through extended development cycles. As mental health becomes an increasingly central concern for society and regulators, funds like Mystic Ventures that combine capital with scientific credibility and founder support will likely define the next generation of transformative healthcare companies.
